Lixisenatide
Lixisenatide
A once-daily GLP-1 receptor agonist (Adlyxin) with a shorter duration of action, providing post-meal glucose control.
Typical Cost
$500-800/month
Status
Research
Peptide Profile
Lixisenatide
Mechanism of Action
Short-acting GLP-1 agonist primarily targeting postprandial glucose. Stimulates insulin secretion after meals. Less effect on fasting glucose compared to longer-acting GLP-1s.
Common Dosages
subcutaneous
10-20mcg
Daily · Ongoing
Benefits
Post-meal glucose control
Daily dosing
Moderate weight loss
Established safety
Side Effects
Nausea
Vomiting
Injection site reactions
Daily injection burden
Key Research
GetGoal trials - Lixisenatide efficacy
Demonstrated postprandial glucose improvements in type 2 diabetes
Regulatory Status
FDA-approved (Adlyxin) for type 2 diabetes. Less commonly prescribed than other GLP-1s.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠Pregnancy/breastfeeding
GLP-1 users benefit from SeraVia formulations regardless of specific GLP-1 medication choice.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.